Skip to main content

Advertisement

Table 1 Patient characteristics

From: Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B

Variables HBeAg (-) (n=39) HBeAg (+) (n=55) P value
no. % no. %  
Age, <40/40-59/60≤ 7/22/10 18/56/26 22/23/10 40/42/18 0.07
Age (y/o) 50.0 ± 11.8 44.3 ± 14.5 0.03
Gender, female/male 11/28 28/72 18/37 33/67 0.7
Drug, LAM/ETV 25/14 64/36 38/17 69/31 0.7
ALT (IU/L), <100/100-199/200≤ 12/16/11 31/41/28 20/13/22 36/24/40 0.19
HBV-DNA (Log copy/mL), <6/6-7.6/7.6< 11/22/6 28/56/15 4/20/31 7/36/56 0.001
Genotype*, B/C 5/26 16/84 1/37 3/97 0.07
HBsAg (IU/mL)*, <1000/1000-10000/10000≤ 7/11/5 30/48/22 3/9/8 15/45/40 0.09
Histology (METAVIR Staging)*, 1/2/3 13/8/6 48/30/22 11/13/7 35/42/23 0.6
Histology (METAVIR Grading)*, 1/2/3 7/17/3 26/63/11 8/15/8 26/48/26 0.3
  1. *Data were not available in some patients